Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
Not Applicable (1)
P 1 (1)
P 3 (1)

Trial Status

Recruiting2
Not Yet Recruiting2

Clinical Trials (4)

Showing 4 of 4 trials
NCT07712562Phase 1Not Yet Recruiting

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Dibotatug (DR-01) in Adults With Bone Marrow Failure Syndromes

NCT07227155RecruitingPrimary

The HOPE Biobank Resource (BMT CTN 2402 HOPE)

NCT06650553Not ApplicableRecruitingPrimary

Umbilical Cord Blood-Supported Haplo-HSCT for Aplastic Anemia Treatment Study

NCT07001397Phase 3Not Yet RecruitingPrimary

Study on the Short-term Efficacy and Safety of Recombinant Human Thrombopoietin Combined With Immunosuppressant Sequential Eltrombopag Ethanolamine Dry Suspension in the Treatment of SAA/TD-NSAA

Showing all 4 trials

Research Network

Activity Timeline